Synopsis
A report indicates that high-cost disease-modifying therapies are set to propel the growth of the Alzheimer's disease market globally, with significant expansions anticipated in key markets over the next decade.Key Takeaways
- Projected growth of Alzheimer's market from $2.4B in 2023 to $19.3B by 2033.
- 73.5% market share expected from disease-modifying therapies (DMTs).
- Challenges include high costs and logistical barriers for new treatments.
- Potential for more effective therapies targeting disease prevention.
- New oral treatments may facilitate easier integration into clinical practice.
New Delhi, Jan 14 (NationPress) High-cost, disease-modifying therapies are projected to significantly drive the expansion of the Alzheimer’s disease market worldwide, as per a detailed analysis.
The study conducted by GlobalData, a leading analytics firm, indicated that this growth will be particularly noticeable in eight key markets: the US, France, Germany, Italy, Spain, the UK, Japan, and China.
The forecast predicts that the Alzheimer’s market in these nations will surge from $2.4 billion in 2023 to $19.3 billion by 2033, achieving a remarkable compound annual growth rate (CAGR) of 23.4%.
This growth trajectory will largely be fueled by the introduction of expensive disease-modifying therapies (DMTs), anticipated to boost treatment rates as more therapeutic options become available. An increasing global population, particularly among the elderly, coupled with a rise in prevalent cases and the debut of innovative symptomatic therapies for managing agitation and psychosis linked to Alzheimer’s, will also play a crucial role in this expansion.
By 2033, it is expected that DMTs will command a significant share of the global Alzheimer’s market, contributing 73.5% of total market revenue, with drugs targeting amyloid beta being predominant, according to the report.
Philippa Salter, the Managing Neurology Analyst at GlobalData, mentioned that Eisai/Biogen’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab) are projected to be leading medications for Alzheimer’s, with anticipated global sales of approximately $3.6 billion and $3.8 billion, respectively, by 2033.
The report also identified challenges for these DMTs, which may hinder their routine clinical application. Key economic and operational barriers include frequent IV administration and the necessity for positron emission tomography (PET) and magnetic resonance imaging (MRI) scans to access these treatments.
“Alongside logistical considerations, these new DMTs are priced significantly higher than the currently available generic symptomatic treatments for Alzheimer’s, creating additional hurdles regarding reimbursement and payer restrictions,” Salter stated.
To address these challenges, pharmaceutical companies are exploring alternative administration methods. Several oral late-stage candidates are being developed that could facilitate easier integration into clinical practice.
Among these are Anavex Life Sciences’ ANAVEX2-73 (blarcamesine), TauRx Therapeutics’ LMTX (hydromethylthionine mesylate), and Novo Nordisk’s NN-6535 (semaglutide).
Despite the new DMTs being regarded as only moderately effective, there is substantial potential for more potent therapies that not only slow the disease’s progression but also aim to halt it entirely, with prevention as the ultimate goal.
In addition to DMTs, medications that can enhance cognitive function in the later stages of the disease, along with more effective treatments for secondary symptoms such as agitation and psychosis, also present significant opportunities for developers.
